Aromatase inhibitors and musculoskeletal adverse events

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages 333-334

  Liedke, Pedro E R ^a   Goss, Paul E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CARPAL TUNNEL SYNDROME; DISEASE SEVERITY; DRUG SAFETY; GENE; GENE EXPRESSION; GENETIC RISK; HUMAN; LETTER; MUSCULOSKELETAL DISEASE; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK REDUCTION; TCL1A GENE; TREATMENT DURATION;

ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARPAL TUNNEL SYNDROME; FEMALE; HUMANS; MUSCULOSKELETAL ABNORMALITIES; TAMOXIFEN;

EID: 84859159461     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70345-X     Document Type: Letter

References (9)

1. Mieog JSD, Morden JP, Bliss JM, Coombes C, van de Velde CJH Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study (IES). Lancet Oncol 2012, on behalf of the IES steering Committee, published online Jan 20. 10.1016/S1470-2045(11)70328-X.
2. Sestak I, Sapunar F, Cuzick J Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009, 27:4961-4965.
3. Huober JB, Cole BF, Wu J, et al. Symptoms of endocrine treatment and outcome: a retrospective analysis of the monotherapy arms of the BIG 1-98 trial. J Clin Oncol 2011, 29(suppl):522.
4. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
5. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364:2381-2391.
6. Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010, 28:4674-4682.
7. Cuzick J, Sestak I, Cella D, Fallowfield L Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9:1143-1148. on behalf of the ATAC Trialists' Group.
8. Kieback DG, Hadji P, Menschik T, Hasenburg A, Tams J, Ziller M Increased progression-free and overall survival in patients with breast cancer with menopausal symptoms or arthralgia/myalgia during adjuvant treatment with exemestane or tamoxifen: results of the German TEAM trial. J Clin Oncol 2011, 29(suppl):523.
9. Stearns V, Chapman JW, Ma CX, et al. Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. J Clin Oncol 2011, 29(suppl):525.